Strategic Funding Astek has secured early-stage funding from TEDCO and other sources, signaling investor confidence and potential for growth capital to accelerate R&D, regulatory pathways, and early commercial pilots. This creates opportunities to align sales pitches with funded timelines and milestone-driven purchasing.

Urine Test Focus The near-term product focus is a urine-based diagnostic that identifies UTIs and antibiotic sensitivity within an hour. This presents a clear entry point for hospital labs, urgent care networks, and telemedicine partners seeking rapid stewardship-enabled decisions and cost reductions.

Multi-Sample Platform JIDDU Platform targets multiple sample types such as urine, CSF, blood, and effluent, enabling cross-hospital adoption across departments including microbiology, infectious disease, and critical care. This broadens potential use cases and contract expansion opportunities.

Strategic Partnerships Active collaborations with institutions like SC2i and MRR Children's Hospital indicate a pipeline of pilot programs and validation studies. Leverage these relationships to position the product for procurement conversations and co-development opportunities.

Regulatory and Research Funding NSF, FDA, BARDA, NIH involvement alongside other funders suggests a favorable regulatory and reimbursement trajectory. This supports building a value-based sales case around performance, cost savings, and patient outcomes to attract hospital systems and payers.